We are live on
!
Find out more
UOC
UBS O'Connor Portfolio holdings
AUM
$3.76B
1-Year Est. Return
62.41%
This Fund
S&P 500
This Quarter
Est. Return
+0.05%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$3.55B
AUM Growth
+$59.4M
(+1.7%)
Cap. Flow
-$31.8M
Cap. Flow
% of AUM
-0.9%
Top 10 Holdings %
Top 10 Hldgs %
49.57%
Holding
665
New
156
Increased
155
Reduced
111
Closed
128
Avg Time Held Equity + Options
3.9
quarters
Top 10 Avg Time Held Equity + Options
0.8
quarters
Top 20 Avg Time Held Equity + Options
1.2
quarters
Avg Time Held Equity only
4.3
quarters
Top 10 Avg Time Held Equity only
0.8
quarters
Top 20 Avg Time Held Equity only
1.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HashiCorp, Inc. Class A Common Stock
HCP
|
+$138M |
| 2 |
Equitrans Midstream Corporation Common Stock
ETRN
|
+$131M |
| 3 |
Endeavor Group Holdings, Inc.
EDR
|
+$127M |
| 4 |
Marathon Oil Corporation
MRO
|
+$123M |
| 5 |
ChampionX
CHX
|
+$98.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pioneer Natural Resource Co.
PXD
|
+$638M |
| 2 |
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$51.2M |
| 3 |
Discover Financial Services
DFS
|
+$45.1M |
| 4 |
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
|
+$18.4M |
| 5 |
Norfolk Southern
NSC
|
+$17.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 26.53% |
| 2 | Technology | 21.03% |
| 3 | Healthcare | 14.68% |
| 4 | Industrials | 8.19% |
| 5 | Miscellaneous | 6.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
451
CALL
Schrodinger
SDGR
$1.97B
| $33.5K | ﹤0.01% |
+70,000
| New | +$1.61M |
2024 Q2
0 quarters
|
|
452
CALL
BioMarin Pharmaceuticals
BMRN
$10.7B
| $33K | ﹤0.01% |
40,000
+15,000
| +60% | +$1.25M |
2023 Q4
2 quarters
|
|
453
PUT
Alnylam Pharmaceuticals
ALNY
$30.7B
| $27.9K | ﹤0.01% |
+19,100
| New | +$3.02M |
2024 Q2
0 quarters
|
|
|
XAGEW
454
DELISTED
Longevity Health Holdings, Inc. Warrant
XAGEW
| $27.1K | ﹤0.01% |
371,250
| – | – |
2023 Q3
3 quarters
|
|
455
CALL
Inspire Medical Systems
INSP
$2.06B
| $26.1K | ﹤0.01% |
+12,000
| New | +$2.27M |
2024 Q2
0 quarters
|
|
456
PUT
Navient
NAVI
$870M
| $26K | ﹤0.01% |
16,500
| – | – |
2021 Q2
12 quarters
|
|
457
CALL
Agios Pharmaceuticals
AGIO
$1.87B
| $25.9K | ﹤0.01% |
45,000
+5,000
| +13% | +$180K |
2024 Q1
1 quarter
|
|
458
PUT
DexCom
DXCM
$32.3B
| $25.9K | ﹤0.01% |
+15,000
| New | +$1.9M |
2024 Q2
0 quarters
|
|
459
PUT
CRISPR Therapeutics
CRSP
$5.03B
| $25.5K | ﹤0.01% |
15,000
-5,000
| -25% | -$289K |
2024 Q1
1 quarter
|
|
460
CALL
uniQure
QURE
$1.5B
| $24K | ﹤0.01% |
+80,000
| New | +$390K |
2024 Q2
0 quarters
|
|
461
CALL
DELISTED
SpringWorks Therapeutics
SWTX
| $24K | ﹤0.01% |
+20,000
| New | +$842K |
2024 Q2
0 quarters
|
|
462
CALL
State Street Health Care Select Sector SPDR ETF
XLV
$44.3B
| $23.4K | ﹤0.01% |
45,000
-35,000
| -44% | -$5.02M |
2024 Q1
1 quarter
|
|
463
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| $23.1K | ﹤0.01% |
+12,500
| New | +$566K |
2024 Q2
0 quarters
|
|
464
CALL
Sanofi
SNY
$95.6B
| $22.5K | ﹤0.01% |
+30,000
| New | +$1.45M |
2024 Q2
0 quarters
|
|
465
PUT
Johnson & Johnson
JNJ
$632B
| $19.9K | ﹤0.01% |
+17,500
| New | +$2.6M |
2024 Q2
0 quarters
|
|
|
BSLKW
466
DELISTED
Bolt Projects Holdings Warrant
BSLKW
| $19.8K | ﹤0.01% |
114,498
| – | – |
2022 Q1
9 quarters
|
|
467
PUT
Antero Midstream
AM
$10B
| $19.2K | ﹤0.01% |
95,800
| – | – |
2024 Q1
1 quarter
|
|
468
PUT
iShares Russell 2000 ETF
IWM
$78.4B
| $18.9K | ﹤0.01% |
+180,000
| New | +$36.4M |
2024 Q2
0 quarters
|
|
469
PUT
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $18.8K | ﹤0.01% |
50,000
| – | – |
2024 Q1
1 quarter
|
|
470
CALL
Baxter International
BAX
$12.7B
| $18K | ﹤0.01% |
+90,000
| New | +$3.32M |
2024 Q2
0 quarters
|
|
471
CALL
Moderna
MRNA
$88.8B
| $17.9K | ﹤0.01% |
16,000
-4,000
| -20% | -$506K |
2023 Q4
2 quarters
|
|
472
CALL
Cytokinetics
CYTK
$8.68B
| $17.8K | ﹤0.01% |
+23,000
| New | +$1.39M |
2024 Q2
0 quarters
|
|
473
DELISTED
APx Acquisition Corp. I Warrant
APXIW
| $17.4K | ﹤0.01% |
91,439
| – | – |
2022 Q1
9 quarters
|
|
474
DELISTED
Jaws Mustang Acquisition Corp. Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
JWSM.WS
| $16.4K | ﹤0.01% |
172,581
| – | – |
2021 Q2
12 quarters
|
|
475
DELISTED
Everest Consolidator Acquisition Corporation Warrants, each whole warrant exercisable for one share of Class A Common Stock, at an exercise price of $11.50
MNTN.WS
| $15.6K | ﹤0.01% |
78,716
| – | – |
2023 Q4
2 quarters
|
|
Similar funds
FNBT
ACI
RC
A
CGL
CB
JCM
MPM
UBS O'Connor's Q2 2024 Portfolio in Review
As of Q2 2024, UBS O'Connor held 665 positions worth $3.55B, up 1.7% from $3.49B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
UBS O'Connor's Q2 2024 filing shows 156 new, 155 increased, 111 reduced and 128 closed positions. Its largest new stake was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M. The largest sale was Pioneer Natural Resource Co., an estimated $638M.
By sector, the portfolio is most concentrated in Energy at 27% of assets, down from 34% a quarter earlier, followed by Technology and Healthcare.
- UBS O'Connor's largest Q2 2024 buy was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M.
- UBS O'Connor added most to HashiCorp, Inc. Class A Common Stock in Q2 2024, an estimated $138M increase.
- UBS O'Connor's biggest Q2 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $51.2M.
- UBS O'Connor fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $638M.
- UBS O'Connor's ten largest holdings make up 50% of its $3.55B portfolio in Q2 2024.
- UBS O'Connor opened 156 new positions and closed 128 in Q2 2024.
- UBS O'Connor's portfolio value rose 1.7% quarter-over-quarter to $3.55B.
Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.